Get the Stockscreener App
29.86
1.77%
0.52
Nektar Therapeutics stock is traded at $29.86, with a volume of 381.71K.
It is up +1.77% in the last 24 hours and up +30.34% over the past month.
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
See More
Previous Close:
$29.34
Open:
$29.53
24h Volume:
381.71K
Relative Volume:
0.18
Market Cap:
$567.89M
Revenue:
$90.12M
Net Income/Loss:
$-276.06M
P/E Ratio:
-20.45
EPS:
-1.46
Net Cash Flow:
$-193.47M
1W Performance:
+10.47%
1M Performance:
+30.34%
6M Performance:
+3,650%
1Y Performance:
+2,251%
1-Day Range:
$28.61
$29.92
1-Week Range:
$26.45
$29.92
52-Week Range:
$0.432
$37.38
Nektar Therapeutics Stock (NKTR) Company Profile
Name
Nektar Therapeutics
Sector
Industry
Phone
(415) 482-5300
Address
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
29.86 | 558.00M | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-24-25 | Reiterated | BTIG Research | Buy |
| Jun-24-25 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-14-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-08-25 | Initiated | B. Riley Securities | Buy |
| Dec-10-24 | Initiated | H.C. Wainwright | Buy |
| Nov-04-24 | Initiated | Piper Sandler | Overweight |
| Sep-30-24 | Resumed | BTIG Research | Buy |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Nov-09-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| May-10-23 | Upgrade | Jefferies | Underperform → Hold |
| Feb-24-23 | Downgrade | Jefferies | Hold → Underperform |
| Aug-08-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-31-22 | Resumed | Jefferies | Hold |
| Apr-18-22 | Downgrade | Goldman | Neutral → Sell |
| Mar-15-22 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-15-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-14-22 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-14-22 | Downgrade | Stifel | Buy → Hold |
| Mar-14-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-09-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-08-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Sep-10-21 | Initiated | BofA Securities | Neutral |
| Jun-28-21 | Upgrade | Stifel | Hold → Buy |
| May-18-21 | Resumed | Goldman | Neutral |
| Feb-22-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jan-06-21 | Initiated | Stifel | Hold |
| Sep-14-20 | Initiated | JP Morgan | Neutral |
| Jun-10-20 | Downgrade | CFRA | Hold → Sell |
| May-12-20 | Reiterated | H.C. Wainwright | Neutral |
| Apr-22-20 | Initiated | The Benchmark Company | Buy |
| Mar-30-20 | Upgrade | Goldman | Sell → Neutral |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-03-20 | Upgrade | Mizuho | Neutral → Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-08-19 | Downgrade | Goldman | Buy → Sell |
| Aug-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-09-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-09-19 | Downgrade | Mizuho | Buy → Neutral |
| Mar-15-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-13-18 | Initiated | Goldman | Buy |
| Jun-11-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-04-18 | Reiterated | H.C. Wainwright | Buy |
| Apr-20-18 | Initiated | Seaport Global Securities | Buy |
| Apr-13-18 | Resumed | Piper Jaffray | Overweight |
| Apr-06-18 | Reiterated | Mizuho | Buy |
| Apr-02-18 | Resumed | H.C. Wainwright | Buy |
View All
Nektar Therapeutics Stock (NKTR) Latest News
Automated trading signals detected on Nektar Therapeutics2025 Market Sentiment & Breakout Confirmation Trade Signals - Newser
Candlestick signals on Nektar Therapeutics stock todayTrade Volume Summary & Stock Market Timing Techniques - Newser
How to build a custom watchlist for Nektar TherapeuticsRate Hike & Weekly Watchlist of Top Performers - Newser
Multi asset correlation models including Nektar TherapeuticsMarket Performance Recap & Advanced Technical Signal Analysis - Newser
What MACD signals say about Nektar Therapeutics2025 Top Decliners & AI Forecasted Entry and Exit Points - Newser
Is Nektar Therapeutics stock ready for a breakoutGap Up & Community Consensus Trade Alerts - Newser
Using data models to predict Nektar Therapeutics stock movement2025 Big Picture & Real-Time Stock Entry Alerts - Newser
Why Nektar Therapeutics stock attracts strong analyst attention2025 Buyback Activity & Fast Gain Stock Trading Tips - Newser
Signal strength of Nektar Therapeutics stock in tech scanners2025 Pullback Review & AI Forecasted Entry/Exit Points - Newser
Using Ichimoku Cloud for Nektar Therapeutics technicals2025 Technical Overview & Smart Investment Allocation Insights - Newser
Nektar Therapeutics stock trend outlook and recovery pathQuarterly Earnings Summary & Capital Efficient Trading Techniques - Newser
Sentiment analysis tools applied to Nektar TherapeuticsShort Setup & AI Enhanced Trade Execution Alerts - Newser
Can Nektar Therapeutics rally from current levelsRecession Risk & Verified High Yield Trade Plans - Newser
How to interpret RSI for Nektar Therapeutics stockJuly 2025 EndofMonth & Capital Protection Trading Alerts - Newser
Applying big data sentiment scoring on Nektar TherapeuticsJuly 2025 Final Week & Risk Adjusted Buy and Sell Alerts - Newser
Comparing Nektar Therapeutics in custom built stock radarsRate Hike & Weekly Watchlist of Top Performers - Newser
Nektar Therapeutics stock volume spike explainedJuly 2025 Technicals & Verified Momentum Stock Watchlist - Newser
What indicators show strength in Nektar TherapeuticsJuly 2025 Pullbacks & Weekly High Conviction Trade Ideas - Newser
News impact scoring models applied to Nektar TherapeuticsMarket Risk Analysis & Long-Term Safe Investment Plans - Newser
Tick level data insight on Nektar Therapeutics volatilityForecast Cut & AI Forecast Swing Trade Picks - Newser
Measuring Nektar Therapeutics’s beta against major indices2025 Year in Review & Reliable Entry Point Trade Alerts - Newser
Can Nektar Therapeutics expand into new markets getLinesFromResByArray error: size == 0 - thegnnews.com
Nektar Therapeutics stock outlook for YEARPortfolio Return Summary & Verified Momentum Stock Ideas - Newser
How to use a screener to detect Nektar Therapeutics breakouts2025 Key Lessons & Weekly Top Stock Performers List - Newser
Certain Stock Options of Nektar Therapeutics are subject to a Lock-Up Agreement Ending on 30-AUG-2025. - MarketScreener
Certain Restricted Stock Units of Nektar Therapeutics are subject to a Lock-Up Agreement Ending on 30-AUG-2025. - MarketScreener
Will Nektar Therapeutics benefit from macro trendsMarket Growth Report & Reliable Price Breakout Alerts - Newser
Nektar Therapeutics Stock (NKTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):